Relmada Therapeutics, Inc.

NasdaqGS:RLMD Stock Report

Market Cap: US$11.4m

Relmada Therapeutics Management

Management criteria checks 3/4

Relmada Therapeutics' CEO is Sergio Traversa, appointed in Apr 2012, has a tenure of 13.08 years. total yearly compensation is $1.80M, comprised of 41.7% salary and 58.3% bonuses, including company stock and options. directly owns 1.16% of the company’s shares, worth $132.07K. The average tenure of the management team and the board of directors is 5.7 years and 5.4 years respectively.

Key information

Sergio Traversa

Chief executive officer

US$1.8m

Total compensation

CEO salary percentage41.7%
CEO tenure13.1yrs
CEO ownership1.2%
Management average tenure5.7yrs
Board average tenure5.4yrs

Recent management updates

Recent updates

Relmada Therapeutics: Run Up Into Results May Resume Following This Drop

Mar 21

Here's Why We're Watching Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Situation

Mar 13
Here's Why We're Watching Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Situation

Relmada: Phase 3 Data Did Not Live Up To Phase 2 Benchmark

Jan 14

Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Deliver On Growth Plans?

Dec 04
Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Deliver On Growth Plans?

Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Invest In Growth?

Aug 29
Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Invest In Growth?

We're Keeping An Eye On Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Rate

May 07
We're Keeping An Eye On Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Rate

We're Keeping An Eye On Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Rate

Dec 15
We're Keeping An Eye On Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Rate

Relmada Downgraded at Truist, Guggenheim in wake of depression candidate failure

Oct 14

Relmada Therapeutics: Initiating With A Strong BUY; Key Phase 3 Short-Term Catalysts Lined Up

Sep 14

Relmada Therapeutics receives FDA fast track tag for REL-1017 to treat depression

Aug 09

We're Hopeful That Relmada Therapeutics (NASDAQ:RLMD) Will Use Its Cash Wisely

Jul 14
We're Hopeful That Relmada Therapeutics (NASDAQ:RLMD) Will Use Its Cash Wisely

Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Deliver On Growth Plans?

Feb 26
Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Deliver On Growth Plans?

4 Clinical Catalysts On Tap For Relmada In 2022

Jan 28

Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Invest In Growth?

Nov 04
Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Invest In Growth?

Our First Look At Relmada Therapeutics

Jun 28

We're Not Very Worried About Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Rate

Jun 28
We're Not Very Worried About Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Rate

Here's Why We're Not Too Worried About Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Situation

Mar 09
Here's Why We're Not Too Worried About Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Situation

What Percentage Of Relmada Therapeutics, Inc. (NASDAQ:RLMD) Shares Do Insiders Own?

Jan 15
What Percentage Of Relmada Therapeutics, Inc. (NASDAQ:RLMD) Shares Do Insiders Own?

CEO Compensation Analysis

How has Sergio Traversa's remuneration changed compared to Relmada Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2024US$2mUS$751k

-US$80m

Sep 30 2024n/an/a

-US$86m

Jun 30 2024n/an/a

-US$87m

Mar 31 2024n/an/a

-US$94m

Dec 31 2023US$2mUS$701k

-US$99m

Sep 30 2023n/an/a

-US$112m

Jun 30 2023n/an/a

-US$129m

Mar 31 2023n/an/a

-US$144m

Dec 31 2022US$3mUS$668k

-US$157m

Sep 30 2022n/an/a

-US$153m

Jun 30 2022n/an/a

-US$157m

Mar 31 2022n/an/a

-US$143m

Dec 31 2021US$36mUS$630k

-US$126m

Sep 30 2021n/an/a

-US$112m

Jun 30 2021n/an/a

-US$86m

Mar 31 2021n/an/a

-US$71m

Dec 31 2020US$900kUS$600k

-US$59m

Sep 30 2020n/an/a

-US$43m

Jun 30 2020n/an/a

-US$30m

Mar 31 2020n/an/a

-US$23m

Dec 31 2019US$16mUS$214k

-US$15m

Sep 30 2019n/an/a

-US$18m

Jun 30 2019n/an/a

-US$17m

Mar 31 2019n/an/a

-US$17m

Dec 31 2018n/an/a

-US$17m

Sep 30 2018n/an/a

-US$11m

Jun 30 2018US$975kUS$376k

-US$9m

Compensation vs Market: Sergio's total compensation ($USD1.80M) is above average for companies of similar size in the US market ($USD681.70K).

Compensation vs Earnings: Sergio's compensation has been consistent with company performance over the past year.

CEO

Sergio Traversa (64 yo)

13.1yrs

Tenure

US$1,800,723

Compensation

Dr. Sergio Traversa, Pharm D., M.B.A. has been the Chief Executive Officer and a Director of Relmada Therapeutics, Inc. since April 18, 2012. Dr. Traversa served as Interim Chief Financial Officer at Relma...

Leadership Team

NamePositionTenureCompensationOwnership
Sergio Traversa
CEO & Director13.1yrsUS$1.80m1.16%
$ 132.1k
Maged Shenouda
Chief Financial Officer5.3yrsUS$993.75k0.27%
$ 30.4k
Paul Kelly
COO & Directorless than a yearUS$872.78k0.64%
$ 73.0k
Charles Ence
Chief Accounting & Compliance Officer5.3yrsUS$983.04k0.12%
$ 13.4k
Gina DiGuglielmo
VP & Head of Clinical Operations6.1yrsno datano data
Andrew Cutler
Senior Clinical Development Advisorno datano datano data
Richard Mangano
Consultant8.1yrsno datano data

5.7yrs

Average Tenure

64yo

Average Age

Experienced Management: RLMD's management team is seasoned and experienced (5.7 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Sergio Traversa
CEO & Director13.1yrsUS$1.80m1.16%
$ 132.1k
Maged Shenouda
Chief Financial Officer5.3yrsUS$993.75k0.27%
$ 30.4k
Paul Kelly
COO & Director9.5yrsUS$872.78k0.64%
$ 73.0k
Charles Casamento
Independent Chairman of the Board9.8yrsUS$353.61k0%
$ 0
Stephen Stahl
Member of Scientific Advisory Board5.3yrsno datano data
Maurizio Fava
Member of Scientific Advisory Board7.9yrsno datano data
Fabiana Fedeli
Independent Director2.3yrsUS$290.64k0%
$ 0
Charles Inturrisi
Member of Scientific Advisory Boardno datano datano data
Paolo Manfredi
Member of Scientific Advisory Boardno datano datano data
John Glasspool
Independent Director5.4yrsUS$286.52kno data
Luca Pani
Member of Scientific Advisory Board5.3yrsno datano data
Dan Iosifescu
Member of Scientific Advisory Board5.3yrsno datano data

5.4yrs

Average Tenure

61yo

Average Age

Experienced Board: RLMD's board of directors are considered experienced (5.4 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/08 23:54
End of Day Share Price 2025/05/08 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Relmada Therapeutics, Inc. is covered by 7 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Maxim JacobsEdison Investment Research
Lin TsaiJefferies LLC
Marc GoodmanLeerink Partners LLC